{
    "clinical_study": {
        "@rank": "164813", 
        "arm_group": {
            "arm_group_label": "dabigatran etexilate", 
            "arm_group_type": "Other", 
            "description": "75mg BID by oral"
        }, 
        "brief_summary": {
            "textblock": "The goal of this study is to assess dabigatran pharmacokinetics in NVAF subjects with severe\n      renal impairment defined as creatinine clearance between 15 and 30 mL/min calculated by\n      Cockcroft-Gault formula.\n\n      The dabigatran etexilate dose of 75 mg BID was approved by the FDA for NVAF patients with\n      severe renal impairment (CrCl 15-30 mL/min) , based on pharmacokinetic modeling and\n      simulation."
        }, 
        "brief_title": "Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Renal Insufficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Subjects diagnosed with non-valvular atrial fibrillation with an indication for the\n             anticoagulation therapy,\n\n          -  Subjects with severe renal function impairment defined as creatinine clearance\n             between 15 and 30 mL/min by Cockcroft-Gault formula,\n\n          -  Male and female patients, age =18 years at entry\n\n        Exclusion criteria:\n\n          -  Contraindications to Pradaxa (history of a serious hypersensitivity reaction to\n             Pradaxa, active pathological bleeding, patients with mechanical prosthetic heart\n             valve),\n\n          -  Creatinine clearance <15ml/min or patients with End Stage Renal Disease on dialysis,\n\n          -  Creatinine clearance >30 ml/min,\n\n          -  Pre-menopausal women (last menstruation less than one year prior to informed consent)\n             who are nursing or pregnant, or are of child bearing potential and are not practicing\n             an acceptable method of birth control, or do not plan to continue using this method\n             throughout the study.  Acceptable methods of birth control include abstinence, tubal\n             ligation, transdermal patch, intra uterine devices/systems (IUDs/IUSs), oral,\n             implantable or injectable contraceptives, double barrier method and vasectomised\n             partner,\n\n          -  Patients who are participating in another drug study,\n\n          -  Patients who have participated in another drug study within 6 weeks,\n\n          -  Patients considered unreliable by the investigator concerning the requirements for\n             participating in the study, including a follow-up interview,\n\n          -  Any condition the investigator believes would not allow safe participation in the\n             study,"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896297", 
            "org_study_id": "1160.173"
        }, 
        "intervention": {
            "arm_group_label": "dabigatran etexilate", 
            "description": "75mg BID by oral", 
            "intervention_name": "Pradaxa, dabigatran etexilate", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hot Springs", 
                        "country": "United States", 
                        "state": "Arkansas"
                    }, 
                    "name": "1160.173.002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fremont", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1160.173.023 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moreno Valley", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1160.173.032 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oceanside", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1160.173.034 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salinas", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1160.173.025 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Pedro", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "1160.173.033 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "Delaware"
                    }, 
                    "name": "1160.173.024 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia"
                    }, 
                    "name": "1160.173.010 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1160.173.036 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1160.173.020 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Largo", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1160.173.012 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1160.173.031 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "1160.173.013 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "1160.173.005 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester Hills", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "1160.173.007 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "1160.173.018 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "1160.173.019 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "1160.173.026 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neptune", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }, 
                    "name": "1160.173.027 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilmington", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "1160.173.014 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Altoona", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "1160.173.001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "1160.173.008 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uniontown", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "1160.173.004 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lancaster", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "1160.173.037 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "1160.173.028 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "1160.173.030 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1160.173.015 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1160.173.011 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Live Oak", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1160.173.006 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1160.173.009 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia"
                    }, 
                    "name": "1160.173.021 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Burien", 
                        "country": "United States", 
                        "state": "Washington"
                    }, 
                    "name": "1160.173.003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waukesha", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }, 
                    "name": "1160.173.035 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pre-dose concentration of the analyte in plasma at steady state immediately before administration of the next dose", 
                "safety_issue": "No", 
                "time_frame": "12 hours"
            }, 
            {
                "measure": "Concentration of analyte in plasma at steady state at 2 hours after administration of the last dose", 
                "safety_issue": "No", 
                "time_frame": "2 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896297"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}